Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.

PURPOSE:The addition of rituximab to standard chemotherapy has significantly improved survival in patients with lymphoma. Recently, maintenance therapy with rituximab has been shown to prevent relapse and provide survival benefits for patients with follicular or mantle cell lymphoma. However, the ef...

Full description

Bibliographic Details
Main Authors:	Xuan Zhou, Tingting Ma, Yichan Zhang, Na Zhou, Juan Li
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5371376?pdf=render

Similar Items

Primary breast diffuse large B-cell lymphoma in the era of rituximab
by: Zhang N, et al.
Published: (2016-10-01)

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
by: Nway Le Ko Ko, et al.
Published: (2020-10-01)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
by: Ulrich Dührsen, et al.
Published: (2018-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
by: Yuan-Rong Ren, et al.
Published: (2015-01-01)

Maintenance therapy for untreated diffuse large B-cell lymphoma: a systematic review and network meta-analysis
by: Ting Yuan, et al.
Published: (2021-05-01)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
by: Steven Habbous, et al.
Published: (2020-10-01)

Identification of novel prognostic biomarkers in diffuse large B cell lymphoma in the rituximab era
by: Johnson, Nathalie
Published: (2010)

Identification of novel prognostic biomarkers in diffuse large B cell lymphoma in the rituximab era
by: Johnson, Nathalie
Published: (2010)

Identification of novel prognostic biomarkers in diffuse large B cell lymphoma in the rituximab era
by: Johnson, Nathalie
Published: (2010)

Maintenance rituximab in Veterans with follicular lymphoma
by: Ahmad S. Halwani, et al.
Published: (2020-10-01)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
by: R. Palmieri, et al.
Published: (2019-01-01)

Comparative Study on Rituximab Combined with Chemotherapy and Single Chemotherapy for Diffuse Large B Cell Lymphoma
by: Ji-feng FENG
Published: (2015-06-01)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
by: Sotirios G. Papageorgiou, et al.
Published: (2021-05-01)

Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma
by: Adriano M. Pellicelli, et al.
Published: (2015-09-01)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
by: Yuankai Shi, et al.
Published: (2020-04-01)

Network meta-analysis of targeted therapies for diffuse large B cell lymphoma
by: Jie Wang, et al.
Published: (2020-12-01)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
by: Feifei Sun, et al.
Published: (2018-01-01)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
by: Myrna Candelaria, et al.
Published: (2021-01-01)

Cryptococcemia in an Elderly Woman with Retroperitoneal Diffuse Large B-cell Lymphoma after Rituximab-containing Chemotherapy
by: Ming-Wei Cheng, et al.
Published: (2016-06-01)

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
by: Carrasquillo J, et al.
Published: (2009-06-01)

Isolated intracardiac recurrence of diffuse large B-cell lymphoma successfully treated with rituximab and bendamustine chemotherapy regimen
by: C H Chang, et al.
Published: (2020-01-01)

Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab?
by: WM Tai MBBS(S'pore), MRCP(UK), et al.
Published: (2011-03-01)

Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment
by: Li-Yangxue Ma, et al.
Published: (2018-01-01)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
by: Hee Kyung Kim, et al.
Published: (2020-01-01)

Diffuse large B cell lymphoma: prognostic factors in the rituximab era = Linfoma B difuso de células grandes: factores pronósticos en la era del rituximab
by: Natalia María Guevara Arismendy, et al.
Published: (2013-07-01)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
by: Lee YP, et al.
Published: (2021-05-01)

Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
by: Martina Bogeljić Patekar, et al.
Published: (2017-01-01)

MicroRNAs are Related to Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Resistance in Patients with Diffuse Large B-cell Lymphoma
by: Haibo Huang, et al.
Published: (2015-01-01)

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
by: Aguiar-Bujanda D, et al.
Published: (2015-10-01)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
by: Kyoung Min Cho, et al.
Published: (2019-07-01)

Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?
by: Sang-Gon Park
Published: (2019-07-01)

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
by: Narendranath Epperla, et al.
Published: (2020-08-01)

Impact of rituximab on standard chemotherapy for diffuse large B-cell lymphoma subtyping using a new immunohistochemistry algorithm
by: Sissolak, Gerhard
Published: (2011)

Excellent response of rituximab and bendamustine in elderly patient with relapsed diffuse large B-cell lymphoma: a case report
by: Wiwiek Probowati, et al.
Published: (2021-01-01)

Rituximab for primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp
by: Čolović Nataša, et al.
Published: (2008-01-01)

Endogenous neurotrophins and Trk signaling in diffuse large B cell lymphoma cell lines are involved in sensitivity to rituximab-induced apoptosis.
by: Cynthia Bellanger, et al.
Published: (2011-01-01)

Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study
by: David Belada, et al.
Published: (2007-01-01)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
by: Koh Ki-Ryang, et al.
Published: (2009-08-01)